Xiumei Feng

Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of relapsed/refractory B-cell lymphomas, yet its initial use in central nervous system lymphoma has been hampered by safety concerns and limited efficacy. Current data are …